Stoke Therapeutics (NASDAQ:STOK) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of Stoke Therapeutics (NASDAQ:STOK) from a hold rating to a sell rating in a report published on Saturday morning.

Other research analysts have also issued reports about the stock. Canaccord Genuity Group upped their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a report on Friday. BTIG Research reiterated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Thursday. Weiss Ratings reissued a “hold (c-)” rating on shares of Stoke Therapeutics in a research note on Monday, December 29th. Guggenheim assumed coverage on Stoke Therapeutics in a research report on Thursday, February 5th. They issued a “buy” rating and a $60.00 target price for the company. Finally, Loop Capital set a $35.00 target price on Stoke Therapeutics in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $41.83.

Stoke Therapeutics Stock Up 1.0%

Shares of STOK opened at $33.51 on Friday. The stock has a market capitalization of $1.98 billion, a P/E ratio of 50.01 and a beta of 1.07. The firm has a fifty day simple moving average of $32.61 and a two-hundred day simple moving average of $30.09. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $40.22.

Insider Buying and Selling

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 4,628 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $145,041.52. Following the transaction, the general counsel directly owned 28,836 shares in the company, valued at approximately $903,720.24. This trade represents a 13.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Barry Ticho sold 6,686 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $209,539.24. Following the completion of the transaction, the insider owned 40,798 shares in the company, valued at $1,278,609.32. The trade was a 14.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 69,699 shares of company stock valued at $2,526,714 in the last 90 days. 9.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC purchased a new position in Stoke Therapeutics during the fourth quarter valued at approximately $26,000. Harbour Investments Inc. increased its stake in Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after buying an additional 898 shares in the last quarter. Generali Investments Management Co LLC bought a new stake in Stoke Therapeutics during the third quarter valued at about $41,000. BNP Paribas Financial Markets raised its holdings in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in shares of Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after acquiring an additional 3,591 shares in the last quarter.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.